 | Up a level |
Faivre, Sandrine J., Santoro, Armando 
ORCID: 0000-0003-1709-9492, Kelley, Robin Kate, Merle, Philippe, Gane, Ed, Douillard, Jean-Yves, Waldschmidt, Dirk, Mulcahy, Mary Frances, Costentin, Charlotte, Minguez, Beatriz ORCID: 0000-0002-7276-9666, Papappicco, Pasqua, Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Lahn, Michael M., Ameryckx, Sophie, Benhadji, Karim A., Raymond, Eric and Giannelli, Gianluigi
(2014).
A phase 2 study of a novel transforming growth factor-beta (TGF-beta 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).
J. Clin. Oncol., 32 (3).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Raymond, Eric, Faivrel, Sandrine, Santoro, Armondo, Kelley, Robin K., Kelley, Robin K., Merle, Philippe, Gane, Ed, Douillard, Jean-Yves, VValdschmidt, Dirk, Mulcahy, Mary, Costentin, Charlotte, Minguez, Beatriz ORCID: 0000-0002-7276-9666, Di Lena, Luca, Gueorguieva, Ivelina, Miles, Colin, Cleverly, Ann, Lahn, Michael M., Ameryckx, Sophie, Benhadji, Karim A. and Giannelli, Gianluigi
(2013).
Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-beta) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients.
Mol. Cancer Ther., 12 (11).
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1538-8514